Metformin; a review of its history and future: from lilac to longevity: THOMAS AND GREGG
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Metformin is a widely prescribed medication that has been used to treat children with type 2 diabetes in the United States for the past 15 years. Metformin now has a variety of clinical applications in pediatrics, and its potential clinical uses continue to expand. In addition to reviewing the current understanding of its mechanisms of action including the newly discovered effects on the gastrointestinal tract, we will also discuss current clinical uses in pediatrics, including in type 1 diabetes. Finally, we examine the existing state of monitoring for metformin efficacy and side effects and discuss prospective future clinical uses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“(DPP) revealed that lifestyle intervention was as or more effective than using metformin to prevent type 2 diabetes.(25,26) Metformin did however reduce progression to type 2 diabetes.”
MethodNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020 · cited 1×
“improvement in weight from initial study baseline; however this effect seems to be driven by participants age 45 and older at randomization.(35) Metformin has also been shown to be mildly beneficial in weight reduction when added to regimens that include medications that cause weight gain, such as antipsychotic medica…”
BackgroundDisentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., et al. (2015) · Nature · doi:10.1038/nature15766 · Cited by 2,116
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399 · cited 1×
“specific but mild inhibitory effect on complex 1 of the mitochondrial respiratory chain.(10) This is thought to change the cellular energy state triggering AMP activated protein kinase (AMPK), a nutrient sensor activated in states of low energy balance.”
BackgroundMetformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284 · cited 1×
“neogenesis via antagonism of the glucagon signaling pathway and also by inhibition of gluconeogenic enzymes in the mitochondria.(14,15)”
BackgroundMetabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148 · cited 1×
“Patients with type 2 diabetes have increased hepatic glucose output at baseline, which is then decreased by 75% in metformin users.(13) Recent studies have found that metformin decreases hepatic gluco-”
BackgroundKirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084 · cited 2×
“3%2%, and the degree of reduction is higher in patients with higher pretreatment blood glucose levels.(19) In a small trial in adolescents, this decrease was 0.”
Background(2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00291-0 · Cited by 1,029
Cited by
AL-Ishaq, R. K., Abotaleb, M., Kubatka, P., Kajo, K., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9090430 · Cited by 741
Romero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., Pacora, P., Yoon, B. H., & Grossman, L. I. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.003 · Cited by 253
Repurposing approved drugs for cancer therapy
Schein, C. H. (2021) · British Medical Bulletin · doi:10.1093/bmb/ldaa045 · Cited by 78
Sodium rutin extends lifespan and health span in mice including positive impacts on liver health
Li, S., Li, J., Pan, R., Cheng, J., Cui, Q., Chen, J., & Yuan, Z. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15410 · Cited by 36
Zhang, Y.-M., Zong, H.-C., Qi, Y.-B., Chang, L.-L., Gao, Y.-N., Zhou, T., Yin, T., Liu, M., Pan, K.-J., Chen, W.-G., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02283-w · Cited by 27
Boudreau, A., Burke, S. J., Collier, J. J., Richard, A. J., Ribnicky, D. M., & Stephens, J. M. (2020) · Obesity · doi:10.1002/oby.22912 · Cited by 14
Metadata
- Authors
- Thomas, I., & Gregg, B.
- Venue
- Pediatric Diabetes
- Publisher
- Hindawi Limited
- Published
- 2017-01-03
- Volume
- 18
- Issue
- 1
- Pages
- 10-16
- ISSN
- 1399-543X (ISSN-L)
- OpenAlex
- W2577535221
- Cited by
- 140
- References
- 15
- FWCI
- 11.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.